Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amikacin + cefotaxime
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo Company
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
A combination antibiotic regimen consisting of amikacin (an aminoglycoside) and cefotaxime (a third-generation cephalosporin). This combination demonstrates synergistic activity against various bacterial pathogens, particularly Gram-negative bacteria including resistant strains. It is primarily used for treating serious infections, especially in neutropenic patients with hematologic malignancies. The synergistic effect enhances bactericidal activity against organisms like Escherichia coli, Klebsiella species, and Pseudomonas aeruginosa.
02
Targets
Beyond the preview
Go deeper on amikacin + cefotaxime.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amikacin + cefotaxime.